Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats

The Journal of Pharmacology and Experimental Therapeutics
Tanuja BordiaMaryka Quik


Antipsychotics are an important class of drugs for the management of schizophrenia and other psychotic disorders. They act by blocking dopamine receptors; however, because these receptors are present throughout the brain, prolonged antipsychotic use also leads to serious side effects. These include tardive dyskinesia, repetitive abnormal involuntary movements of the face and limbs for which there is little treatment. In this study, we investigated whether nicotine administration could reduce tardive dyskinesia because nicotine attenuates other drug-induced abnormal movements. We used a well established model of tardive dyskinesia in which rats injected with the commonly used antipsychotic haloperidol develop vacuous chewing movements (VCMs) that resemble human orofacial dyskinesias. Rats were first administered nicotine (minipump; 2 mg/kg per day). Two weeks later, they were given haloperidol (1 mg/kg s.c.) once daily. Nicotine treatment reduced haloperidol-induced VCMs by ∼20% after 5 weeks, with a significant ∼60% decline after 13 weeks. There was no worsening of haloperidol-induced catalepsy. To understand the molecular basis for this improvement, we measured the striatal dopamine transporter and nicotinic acetylcholine rece...Continue Reading


Jul 15, 1991·Biological Psychiatry·M A MenzaN Forman
Jun 1, 1990·Journal of Neuroscience Methods·R ArtymyshynB B Wolfe
Jan 1, 1987·Biological Psychiatry·R YassaJ Ally
Jul 1, 1972·European Journal of Pharmacology·K Kuschinsky, O Hornykiewicz
Jul 1, 1998·Journal of Neurology, Neurosurgery, and Psychiatry·M F MazurekP I Rosebush
May 27, 2005·PLoS Medicine·Sukanta SahaJohn McGrath
Jun 14, 2005·Biological Psychiatry·Bertha K MadrasAlan J Fischman
Aug 2, 2005·Journal of Neuroscience Methods·Sonja B SchleimerJasmine M Henderson
Aug 3, 2006·Journal of Neurochemistry·Maryka QuikDonato Di Monte
Aug 10, 2006·Psychopharmacology·Shannon G MattaJeffrey M Zirger
Apr 7, 2007·Trends in Pharmacological Sciences·Maryka QuikXiomara A Perez
Oct 26, 2007·Annals of Neurology·Maryka QuikDonato Di Monte
Nov 6, 2007·Frontiers in Bioscience : a Journal and Virtual Library·Marina R Picciotto, Michele Zoli
Feb 5, 2008·Schizophrenia Research·Rajiv TandonSection of Pharmacopsychiatry, World Psychiatric Association
Feb 26, 2008·Biological Psychiatry·Anne-Noël SamahaShitij Kapur
Aug 30, 2008·Neuropharmacology·Neil S Millar, Cecilia Gotti
Sep 9, 2008·European Psychiatry : the Journal of the Association of European Psychiatrists·A DiehlW F Gattaz
Jan 8, 2009·Physiological Reviews·Edson X AlbuquerqueScott W Rogers
Jun 2, 2009·Biochemical Pharmacology·Cecilia GottiMichele Zoli
Mar 5, 2010·The Journal of Pharmacology and Experimental Therapeutics·Tanuja BordiaMaryka Quik
May 21, 2010·Nature Reviews. Neuroscience·Jean-Pierre Changeux
Jul 21, 2010·Clinical Schizophrenia & Related Psychoses·Philip Seeman
Aug 11, 2010·Progress in Brain Research·M Angela Cenci, Christine Konradi
Mar 3, 2011·Current Treatment Options in Neurology·Pratibha G AiaStewart A Factor
Mar 24, 2011·Frontiers in Systems Neuroscience·Sarah Threlfell, Stephanie Jane Cragg
Apr 19, 2011·Handbook of Clinical Neurology·Oscar S Gershanik, Gonzalo J Gómez Arévalo
Apr 19, 2011·Handbook of Clinical Neurology·Daniel TarsyRoss J Baldessarini
Jun 15, 2011·The Journal of Pharmacology and Experimental Therapeutics·Luping Z HuangMaryka Quik
Jul 5, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Xiang Yang ZhangThomas R Kosten
Oct 5, 2011·Pharmacological Reviews·Maryka Quik, Susan Wonnacott


Jan 31, 2013·Experimental Neurology·Nicolas MorinThérèse Di Paolo
May 20, 2014·Pharmacology & Therapeutics·Maryka QuikTanuja Bordia
Jan 14, 2017·Frontiers in Psychiatry·Ryoma MorigakiSatoshi Goto
Oct 4, 2017·Expert Review of Neurotherapeutics·Thomas Müller
Jul 29, 2017·Expert Review of Neurotherapeutics·Haitham SalemAntonio L Teixeira
Oct 26, 2018·Drugs & Aging·Carlos Estevez-FragaJose Luis López-Sendón Moreno
Aug 24, 2018·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Maryka QuikXiomara A Perez
Oct 31, 2020·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Stanley N Caroff

Related Concepts

Nicotinic receptor alpha4beta2
Alpha6beta2 nicotinic acetylcholine receptor, rat
Waxy Flexibility
Lentiform Nucleus Structure
Dyskinesia, Medication-Induced
Etat Marbre
Nicotinic Receptors
Antipsychotic Effect

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here